NCT06806462 Biomolecular Markers of Bone Metastasis
| NCT ID | NCT06806462 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Bone Metastasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-09-17 |
| Primary Completion | 2026-06-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2024-09-17 with a primary completion date of 2026-06-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to characterize the biomolecular profile of bone metastases to define the predisposing profiles of bone metastasis, in patients with breast or lung or renal carcinomas or of the gastroenteric or prostate tract with bone metastasis. The main question it aims to answer is: Is it possible to predict the progression of bone metastasis by identifying biomarkers as risk factors for bone metastasis?
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Patients with breast or lung or renal or gastroenteric tract or prostate with bone metastases * Patients who knowingly express willingness to participate in the study after signing the written informed consent Exclusion Criteria: * None
Contact & Investigator
Andrea Sambri, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06806462 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06806462 currently recruiting?
Yes, NCT06806462 is actively recruiting participants. Contact the research team at andrea.sambri@aosp.bo.it for enrollment information.
Where is the NCT06806462 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06806462 clinical trial?
NCT06806462 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Andrea Sambri, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 160 participants.